Sacubitril/Valsartan Alleviates Experimental Autoimmune Myocarditis by Inhibiting Th17 Cell Differentiation Independently of the NLRP3 Inflammasome Pathway
Sacubitril/valsartan (Sac/Val) is a recently approved drug that is commonly used for treatment of heart failure. Several studies indicated that Sac/Val also regulated the secretion of inflammatory factors. However, the effect and mechanism of this drug modulation of inflammatory immune responses are...
Saved in:
Main Authors: | Wei Liang (Author), Bai-Kang Xie (Author), Pei-Wu Ding (Author), Min Wang (Author), Jing Yuan (Author), Xiang Cheng (Author), Yu-Hua Liao (Author), Miao Yu (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sacubitril/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats
by: Wenchao Zhang, et al.
Published: (2021) -
Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
by: Nor Hidayah Mustafa, et al.
Published: (2022) -
Sacubitril/valsartan in real-life clinical practice
by: Yüksel Çavuşoğlu
Published: (2021) -
Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
by: Sarah L Anderson, et al.
Published: (2018) -
Sacubitril/valsartan: research progress of multi-channel therapy for cardiorenal syndrome
by: Shuangcui Wang, et al.
Published: (2023)